A Philadelphia jury slammed Johnson & Johnson subsidiary Ethicon Inc. with a $41 million verdict on Thursday, Jan. 31 after finding that defects in a mesh implant manufactured by the company left a woman with permanent injuries after the product eroded through her pelvis.
This verdict is the latest in a wave of multimillion-dollar verdicts that juries have awarded over Ethicon’s mesh products. There are now more than 100,000 pelvic mesh cases pending across the country.
Ethicon Concealed High Failure Rate in Mesh Product
The jurors agreed that Ethicon had negligently designed the mesh implants and failed to provide proper warnings that the devices could erode through soft tissue in the pelvis and cause permanent scarring and other injuries.
The plaintiff, Suzanne Emmett, received three mesh implants to treat urinary incontinence, bladder contractions, and organ prolapse. She filed suit in July 2013 after experiencing severe complications. In the weeks after receiving the implants in May 2007, her attorneys said she began to experience serious complications as a portion of one of the devices eroded into her pelvis.
The plaintiff’s attorneys urged jurors to hold the Johnson & Johnson company accountable for a lack of clinical trials before putting their pelvis mesh implants on the market. Jurors took that message to heart, awarding $25 million in punitive damages as part of their verdict following a five-week trial.
The grand total that Ethicon faces includes $15 million in compensatory damages, $25 million in punitive damages and $1 million on a loss of consortium claim.
Cory Watson Attorneys Fight For Justice
Our principal and managing shareholder, Ernest Cory, has been the National Co-Trial Counsel of the Kugel Hernia Mesh litigation since its launch over a decade ago. Over 4,000 cases have been resolved under his leadership. Principal attorneys Jon C. Conlin and Stephen Hunt have been instrumental in fighting for pelvic mesh victims to receive compensation.
Our goal? To hold these corporate giants liable for putting profits over patients.